NCT05815407

Brief Summary

Its to explore the expression pattern, diagnostic and prognostic potentials of miRs (106b-5p, 601 and 760) in serum of NSCLC patients

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Sep 2018

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2018

Completed
4.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 30, 2022

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

April 4, 2023

Completed
14 days until next milestone

First Posted

Study publicly available on registry

April 18, 2023

Completed
Last Updated

April 18, 2023

Status Verified

April 1, 2023

Enrollment Period

4.1 years

First QC Date

April 4, 2023

Last Update Submit

April 4, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • Determination of the expression

    Expression profiling of the selected miRNAs

    By the end of the study (September 2022)

Study Arms (2)

NSCLC patients

Patients were diagnosed with NSCLC at any stage, then will be subdivided into Early stage, Lympho-node involvement stage and Distant metastatic stage

Other: No intervention

Control subjects

Appearantly healthy age-matched individuals

Other: No intervention

Interventions

No intervention

Control subjectsNSCLC patients

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Case-control

You may qualify if:

  • First time and recently diagnosed NSCLC patient

You may not qualify if:

  • Recurrent NSCLC
  • Start of chemotherapy, radiotherapy or surgical intervention
  • Previous treatment
  • Cancer history

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt

Cairo, 11231, Egypt

Location

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Condition Hierarchy (Ancestors)

Carcinoma, BronchogenicBronchial NeoplasmsLung NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract Diseases

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor Associate of Medical Biochemistry and Molecular Biology

Study Record Dates

First Submitted

April 4, 2023

First Posted

April 18, 2023

Study Start

September 1, 2018

Primary Completion

September 30, 2022

Study Completion

September 30, 2022

Last Updated

April 18, 2023

Record last verified: 2023-04

Locations